



J&J COVID-19 Vaccine – ACIP Recommends Continued Use

- On April 23, 2021, the [CDC's Advisory Committee on Immunization Practices \(ACIP\) convened an emergency meeting](#) to reassess the risk benefit profile of the Johnson & Johnson (J&J) coronavirus vaccine.
- After reviewing the current data, hearing from J&J, and deliberating on different options, they decided to reaffirm their original recommendations for the vaccine for ages and genders. The recommendation is:
 - *The Janssen (J&J) COVID-19 vaccine is recommended for persons 18 years of age and older in the U.S. population under the FDA's Emergency Use Authorization.*
- There were 10 votes in favor to 4 votes against and 1 abstaining (due to conflict of interest). Dissenting members were in favor of an alternative option that specifically described the risk of clotting in women age < 50 years and that they may choose an alternative. After considerable discussion the ACIP felt that the recommendation should be clear, simple, and unambiguous to facilitate communication and implementation.
- The J&J COVID-19 vaccine will remain on the U.S. Market
- Additional risk information will be added to the J&J vaccine label in the form of a boxed warning, and the patient fact sheet will include new language advising of the risk of blood clots in women less than 50 years old.
- Additional communications are expected from the FDA and CDC early next week, including updated clinical considerations for use which will describe the risks in more detail.
- To date, [7.98 million doses](#) of the J&J vaccine have been administered and 15 cases of an atypical clotting event (thrombosis and thrombocytopenia syndrome) have been detected. No cases have been detected with the mRNA vaccines from Pfizer/BioNTech and Moderna.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.